Taysha Gene Therapies Proposes Public Offering of Stock and Warrants

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a biotechnology firm in the clinical stage, is committed to developing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system (CNS) diseases. On June 25, 2024, the company announced the launch of a public offering to raise up to $75 million by selling common stock and pre-funded warrants to certain investors. All offered securities will be provided by Taysha itself. Additionally, the company plans to grant underwriters a 30-day option to purchase up to 15% more shares under the same conditions.

The completion of this offering is contingent on market conditions and is not guaranteed. Jefferies and Goldman Sachs & Co. LLC are the main managers for this offering, with Cantor also participating as a book-running manager. The offering will adhere to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on October 5, 2021, and made effective on October 14, 2021. The official offering will be conducted through written prospectus supplements, available on the SEC's website.

Taysha Gene Therapies is focused on creating transformative medicines to address severe medical needs. Their leading clinical program, TSHA-102, is being developed for Rett syndrome, a rare neurodevelopmental disorder with no current therapies addressing its genetic cause. The company's leadership has extensive experience in gene therapy development and commercialization, helping to quickly advance treatments from laboratory research to clinical settings.